Androgen Deprivation Therapy
Androgen Deprivation Therapy

Androgen Deprivation Therapy Comprehensive Study by Type (Luteinizing Hormone-Releasing Hormone (LHRH) agonists, LHRH antagonists, Antiandrogens, Others), End-User (Hospitals, Clinics, Others), Administration Route (Injectable, Oral), Patients (Adult, Kids) Players and Region - Global Market Outlook to 2026

Androgen Deprivation Therapy Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

May 2021 Edition 221 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Androgen Deprivation Therapy Market?

The growth of the world androgen deprivation therapy market is driven by the rising cases and deaths of prostate cancer, innovative technologies, advancing care expenditure and facilities, increasing international awareness and demand for higher treatment. The R&D bodies are actively dwelling to develop novel androgen deprivation therapy for cancer. The approval of the latest medicine has additionally propelled the androgen deprivation therapy market growth. However, the market growth is constrained by the resistance developed throughout the treatments, facet effects like hot flashes, disfunction, low bone density, insulin resistance, etc. Androgen deprivation therapy is ineffective for hormone-refractory prostate cancer. The high expenses and poor compensation of treatment expenses hinder the market growth. Although, the international androgen deprivation therapy market is anticipated to grow in addition due to the increasing cases of prostate cancer, rising R&D and care facilities.

The market study is being classified by Type (Luteinizing Hormone-Releasing Hormone (LHRH) agonists, LHRH antagonists, Antiandrogens and Others) and major geographies with country level break-up.

Abbott Laboratories (United States), Genentech Inc. (United States), GlaxoSmithKline Plc (United Kingdom), Immunomedics Inc. (United States), Allergan plc (India), Amgen (United States), Bayer AG (Germany), AstraZeneca (United Kingdom), Johnson & Johnson (United States), Pfizer (United States) and Sanofi (France) are some of the key players profiled in the study.

The prevalence of Prostate Cancer has increased the market for Androgen Deprivation Therapy. The rise in the expenditure on healthcare has also increased the market along with the rising geriatric population. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Androgen Deprivation Therapy market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Androgen Deprivation Therapy market by Type, Application and Region.

On the basis of geography, the market of Androgen Deprivation Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Expenditure on Healthcare
  • High Prevalence of The Prostate Cancer
  • Increased Demand for Better and Efficient Technique

Market Trend
  • Rapid Adoption of The Therapy

Restraints
  • High Cost Associated with The Therapy

Opportunities
  • Improved Technology and Massive Research Investments
  • Increasing Government Initiatives

Challenges
  • Lack of Awareness
  • Poor Reimbursement of The Treatment Expense





Key Target Audience
Providers of Androgen Deprivation Therapy, Governmental and Regulatory bodies, End-Users and Potential Investors

Frequently Asked Questions (FAQ):

1. Which factors would majorly drive the Androgen Deprivation Therapy Market?
"Increased Expenditure on Healthcare " is seen as one of major growth factors of Androgen Deprivation Therapy Market in years to come.

2. Can we have customized study for Androgen Deprivation Therapy Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Report Objectives / Segmentation Covered
By Type
  • Luteinizing Hormone-Releasing Hormone (LHRH) agonists
  • LHRH antagonists
  • Antiandrogens
  • Others
By End-User
  • Hospitals
  • Clinics
  • Others

By Administration Route
  • Injectable
  • Oral

By Patients
  • Adult
  • Kids

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Expenditure on Healthcare
      • 3.2.2. High Prevalence of The Prostate Cancer
      • 3.2.3. Increased Demand for Better and Efficient Technique
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness
      • 3.3.2. Poor Reimbursement of The Treatment Expense
    • 3.4. Market Trends
      • 3.4.1. Rapid Adoption of The Therapy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Androgen Deprivation Therapy, by Type, End-User, Administration Route, Patients and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Androgen Deprivation Therapy (Value)
      • 5.2.1. Global Androgen Deprivation Therapy by: Type (Value)
        • 5.2.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) agonists
        • 5.2.1.2. LHRH antagonists
        • 5.2.1.3. Antiandrogens
        • 5.2.1.4. Others
      • 5.2.2. Global Androgen Deprivation Therapy by: End-User (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Androgen Deprivation Therapy by: Administration Route (Value)
        • 5.2.3.1. Injectable
        • 5.2.3.2. Oral
      • 5.2.4. Global Androgen Deprivation Therapy by: Patients (Value)
        • 5.2.4.1. Adult
        • 5.2.4.2. Kids
      • 5.2.5. Global Androgen Deprivation Therapy Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Androgen Deprivation Therapy (Price)
      • 5.3.1. Global Androgen Deprivation Therapy by: Type (Price)
  • 6. Androgen Deprivation Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Genentech Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Immunomedics Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Allergan plc (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Amgen (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bayer AG (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AstraZeneca (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Johnson & Johnson (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pfizer (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Sanofi (France)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Androgen Deprivation Therapy Sale, by Type, End-User, Administration Route, Patients and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Androgen Deprivation Therapy (Value)
      • 7.2.1. Global Androgen Deprivation Therapy by: Type (Value)
        • 7.2.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) agonists
        • 7.2.1.2. LHRH antagonists
        • 7.2.1.3. Antiandrogens
        • 7.2.1.4. Others
      • 7.2.2. Global Androgen Deprivation Therapy by: End-User (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Androgen Deprivation Therapy by: Administration Route (Value)
        • 7.2.3.1. Injectable
        • 7.2.3.2. Oral
      • 7.2.4. Global Androgen Deprivation Therapy by: Patients (Value)
        • 7.2.4.1. Adult
        • 7.2.4.2. Kids
      • 7.2.5. Global Androgen Deprivation Therapy Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Androgen Deprivation Therapy (Price)
      • 7.3.1. Global Androgen Deprivation Therapy by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Androgen Deprivation Therapy: by Type(USD Million)
  • Table 2. Androgen Deprivation Therapy Luteinizing Hormone-Releasing Hormone (LHRH) agonists , by Region USD Million (2015-2020)
  • Table 3. Androgen Deprivation Therapy LHRH antagonists , by Region USD Million (2015-2020)
  • Table 4. Androgen Deprivation Therapy Antiandrogens , by Region USD Million (2015-2020)
  • Table 5. Androgen Deprivation Therapy Others , by Region USD Million (2015-2020)
  • Table 6. Androgen Deprivation Therapy: by End-User(USD Million)
  • Table 7. Androgen Deprivation Therapy Hospitals , by Region USD Million (2015-2020)
  • Table 8. Androgen Deprivation Therapy Clinics , by Region USD Million (2015-2020)
  • Table 9. Androgen Deprivation Therapy Others , by Region USD Million (2015-2020)
  • Table 10. Androgen Deprivation Therapy: by Administration Route(USD Million)
  • Table 11. Androgen Deprivation Therapy Injectable , by Region USD Million (2015-2020)
  • Table 12. Androgen Deprivation Therapy Oral , by Region USD Million (2015-2020)
  • Table 13. Androgen Deprivation Therapy: by Patients(USD Million)
  • Table 14. Androgen Deprivation Therapy Adult , by Region USD Million (2015-2020)
  • Table 15. Androgen Deprivation Therapy Kids , by Region USD Million (2015-2020)
  • Table 16. South America Androgen Deprivation Therapy, by Country USD Million (2015-2020)
  • Table 17. South America Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 18. South America Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 19. South America Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 20. South America Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 21. Brazil Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 22. Brazil Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 23. Brazil Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 24. Brazil Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 25. Argentina Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 26. Argentina Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 27. Argentina Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 28. Argentina Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 29. Rest of South America Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 30. Rest of South America Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 31. Rest of South America Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 32. Rest of South America Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 33. Asia Pacific Androgen Deprivation Therapy, by Country USD Million (2015-2020)
  • Table 34. Asia Pacific Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 35. Asia Pacific Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 36. Asia Pacific Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 37. Asia Pacific Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 38. China Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 39. China Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 40. China Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 41. China Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 42. Japan Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 43. Japan Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 44. Japan Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 45. Japan Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 46. India Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 47. India Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 48. India Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 49. India Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 50. South Korea Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 51. South Korea Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 52. South Korea Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 53. South Korea Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 54. Taiwan Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 55. Taiwan Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 56. Taiwan Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 57. Taiwan Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 58. Australia Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 59. Australia Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 60. Australia Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 61. Australia Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 66. Europe Androgen Deprivation Therapy, by Country USD Million (2015-2020)
  • Table 67. Europe Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 68. Europe Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 69. Europe Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 70. Europe Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 71. Germany Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 72. Germany Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 73. Germany Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 74. Germany Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 75. France Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 76. France Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 77. France Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 78. France Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 79. Italy Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 80. Italy Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 81. Italy Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 82. Italy Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 83. United Kingdom Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 84. United Kingdom Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 85. United Kingdom Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 86. United Kingdom Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 87. Netherlands Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 88. Netherlands Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 89. Netherlands Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 90. Netherlands Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 91. Rest of Europe Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 92. Rest of Europe Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 93. Rest of Europe Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 94. Rest of Europe Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 95. MEA Androgen Deprivation Therapy, by Country USD Million (2015-2020)
  • Table 96. MEA Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 97. MEA Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 98. MEA Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 99. MEA Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 100. Middle East Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 101. Middle East Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 102. Middle East Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 103. Middle East Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 104. Africa Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 105. Africa Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 106. Africa Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 107. Africa Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 108. North America Androgen Deprivation Therapy, by Country USD Million (2015-2020)
  • Table 109. North America Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 110. North America Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 111. North America Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 112. North America Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 113. United States Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 114. United States Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 115. United States Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 116. United States Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 117. Canada Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 118. Canada Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 119. Canada Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 120. Canada Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 121. Mexico Androgen Deprivation Therapy, by Type USD Million (2015-2020)
  • Table 122. Mexico Androgen Deprivation Therapy, by End-User USD Million (2015-2020)
  • Table 123. Mexico Androgen Deprivation Therapy, by Administration Route USD Million (2015-2020)
  • Table 124. Mexico Androgen Deprivation Therapy, by Patients USD Million (2015-2020)
  • Table 125. Androgen Deprivation Therapy: by Type(USD/Units)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Androgen Deprivation Therapy: by Type(USD Million)
  • Table 138. Androgen Deprivation Therapy Luteinizing Hormone-Releasing Hormone (LHRH) agonists , by Region USD Million (2021-2026)
  • Table 139. Androgen Deprivation Therapy LHRH antagonists , by Region USD Million (2021-2026)
  • Table 140. Androgen Deprivation Therapy Antiandrogens , by Region USD Million (2021-2026)
  • Table 141. Androgen Deprivation Therapy Others , by Region USD Million (2021-2026)
  • Table 142. Androgen Deprivation Therapy: by End-User(USD Million)
  • Table 143. Androgen Deprivation Therapy Hospitals , by Region USD Million (2021-2026)
  • Table 144. Androgen Deprivation Therapy Clinics , by Region USD Million (2021-2026)
  • Table 145. Androgen Deprivation Therapy Others , by Region USD Million (2021-2026)
  • Table 146. Androgen Deprivation Therapy: by Administration Route(USD Million)
  • Table 147. Androgen Deprivation Therapy Injectable , by Region USD Million (2021-2026)
  • Table 148. Androgen Deprivation Therapy Oral , by Region USD Million (2021-2026)
  • Table 149. Androgen Deprivation Therapy: by Patients(USD Million)
  • Table 150. Androgen Deprivation Therapy Adult , by Region USD Million (2021-2026)
  • Table 151. Androgen Deprivation Therapy Kids , by Region USD Million (2021-2026)
  • Table 152. South America Androgen Deprivation Therapy, by Country USD Million (2021-2026)
  • Table 153. South America Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 154. South America Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 155. South America Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 156. South America Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 157. Brazil Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 158. Brazil Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 159. Brazil Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 160. Brazil Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 161. Argentina Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 162. Argentina Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 163. Argentina Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 164. Argentina Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 165. Rest of South America Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 166. Rest of South America Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 167. Rest of South America Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 168. Rest of South America Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 169. Asia Pacific Androgen Deprivation Therapy, by Country USD Million (2021-2026)
  • Table 170. Asia Pacific Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 171. Asia Pacific Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 172. Asia Pacific Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 173. Asia Pacific Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 174. China Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 175. China Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 176. China Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 177. China Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 178. Japan Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 179. Japan Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 180. Japan Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 181. Japan Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 182. India Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 183. India Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 184. India Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 185. India Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 186. South Korea Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 187. South Korea Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 188. South Korea Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 189. South Korea Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 190. Taiwan Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 191. Taiwan Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 192. Taiwan Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 193. Taiwan Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 194. Australia Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 195. Australia Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 196. Australia Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 197. Australia Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 198. Rest of Asia-Pacific Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 199. Rest of Asia-Pacific Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 200. Rest of Asia-Pacific Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 201. Rest of Asia-Pacific Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 202. Europe Androgen Deprivation Therapy, by Country USD Million (2021-2026)
  • Table 203. Europe Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 204. Europe Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 205. Europe Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 206. Europe Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 207. Germany Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 208. Germany Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 209. Germany Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 210. Germany Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 211. France Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 212. France Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 213. France Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 214. France Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 215. Italy Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 216. Italy Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 217. Italy Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 218. Italy Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 219. United Kingdom Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 220. United Kingdom Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 221. United Kingdom Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 222. United Kingdom Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 223. Netherlands Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 224. Netherlands Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 225. Netherlands Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 226. Netherlands Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 227. Rest of Europe Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 228. Rest of Europe Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 229. Rest of Europe Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 230. Rest of Europe Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 231. MEA Androgen Deprivation Therapy, by Country USD Million (2021-2026)
  • Table 232. MEA Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 233. MEA Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 234. MEA Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 235. MEA Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 236. Middle East Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 237. Middle East Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 238. Middle East Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 239. Middle East Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 240. Africa Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 241. Africa Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 242. Africa Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 243. Africa Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 244. North America Androgen Deprivation Therapy, by Country USD Million (2021-2026)
  • Table 245. North America Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 246. North America Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 247. North America Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 248. North America Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 249. United States Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 250. United States Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 251. United States Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 252. United States Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 253. Canada Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 254. Canada Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 255. Canada Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 256. Canada Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 257. Mexico Androgen Deprivation Therapy, by Type USD Million (2021-2026)
  • Table 258. Mexico Androgen Deprivation Therapy, by End-User USD Million (2021-2026)
  • Table 259. Mexico Androgen Deprivation Therapy, by Administration Route USD Million (2021-2026)
  • Table 260. Mexico Androgen Deprivation Therapy, by Patients USD Million (2021-2026)
  • Table 261. Androgen Deprivation Therapy: by Type(USD/Units)
  • Table 262. Research Programs/Design for This Report
  • Table 263. Key Data Information from Secondary Sources
  • Table 264. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Androgen Deprivation Therapy: by Type USD Million (2015-2020)
  • Figure 5. Global Androgen Deprivation Therapy: by End-User USD Million (2015-2020)
  • Figure 6. Global Androgen Deprivation Therapy: by Administration Route USD Million (2015-2020)
  • Figure 7. Global Androgen Deprivation Therapy: by Patients USD Million (2015-2020)
  • Figure 8. South America Androgen Deprivation Therapy Share (%), by Country
  • Figure 9. Asia Pacific Androgen Deprivation Therapy Share (%), by Country
  • Figure 10. Europe Androgen Deprivation Therapy Share (%), by Country
  • Figure 11. MEA Androgen Deprivation Therapy Share (%), by Country
  • Figure 12. North America Androgen Deprivation Therapy Share (%), by Country
  • Figure 13. Global Androgen Deprivation Therapy: by Type USD/Units (2015-2020)
  • Figure 14. Global Androgen Deprivation Therapy share by Players 2020 (%)
  • Figure 15. Global Androgen Deprivation Therapy share by Players (Top 3) 2020(%)
  • Figure 16. Global Androgen Deprivation Therapy share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 19. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 20. Genentech Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Genentech Inc. (United States) Revenue: by Geography 2020
  • Figure 22. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2020
  • Figure 24. Immunomedics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Immunomedics Inc. (United States) Revenue: by Geography 2020
  • Figure 26. Allergan plc (India) Revenue, Net Income and Gross profit
  • Figure 27. Allergan plc (India) Revenue: by Geography 2020
  • Figure 28. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 29. Amgen (United States) Revenue: by Geography 2020
  • Figure 30. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 31. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 32. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 34. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 35. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 36. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 37. Pfizer (United States) Revenue: by Geography 2020
  • Figure 38. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 39. Sanofi (France) Revenue: by Geography 2020
  • Figure 40. Global Androgen Deprivation Therapy: by Type USD Million (2021-2026)
  • Figure 41. Global Androgen Deprivation Therapy: by End-User USD Million (2021-2026)
  • Figure 42. Global Androgen Deprivation Therapy: by Administration Route USD Million (2021-2026)
  • Figure 43. Global Androgen Deprivation Therapy: by Patients USD Million (2021-2026)
  • Figure 44. South America Androgen Deprivation Therapy Share (%), by Country
  • Figure 45. Asia Pacific Androgen Deprivation Therapy Share (%), by Country
  • Figure 46. Europe Androgen Deprivation Therapy Share (%), by Country
  • Figure 47. MEA Androgen Deprivation Therapy Share (%), by Country
  • Figure 48. North America Androgen Deprivation Therapy Share (%), by Country
  • Figure 49. Global Androgen Deprivation Therapy: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Abbott Laboratories (United States)
  • Genentech Inc. (United States)
  • GlaxoSmithKline Plc (United Kingdom)
  • Immunomedics Inc. (United States)
  • Allergan plc (India)
  • Amgen (United States)
  • Bayer AG (Germany)
  • AstraZeneca (United Kingdom)
  • Johnson & Johnson (United States)
  • Pfizer (United States)
  • Sanofi (France)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation